- Home
- GLV vs ALGS Comparison
GLV vs ALGS Comparison
Compare GLV & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLV | ALGS |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 62.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLV | ALGS |
|---|---|---|
| Price | $6.31 | $8.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 54.2K | ★ 62.4K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | ★ 12.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.70 | $3.76 |
| 52 Week High | $6.06 | $34.37 |
Technical Indicators
Market Signals| Indicator | GLV | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 71.72 | 39.90 |
| Support Level | $6.19 | $8.39 |
| Resistance Level | $6.27 | $9.39 |
| Average True Range (ATR) | 0.06 | 0.85 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 97.37 | 1.61 |
Price Performance
Historical ComparisonAbout GLV Clough Global Dividend and Income Fund of beneficial interest
Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.